94
Faculty Disclosures
Lundbeck. He has held research grants from Lilly
and Lundbeck. He is an editor of Psychopharmacol-
ogy (Springer Verlag).
Russo, Scott:
Disclosure: None
Sahakian, Barbara J.:
Disclosure: Barbara Sahakian
consults for Cambridge Cognition, Lundbeck, Ser-
vier, Roche and holds a grant from Janssen/J&J. She
also receives funding from the Wellcome Trust and
is a member of the MRC/Wellcome Trust Behav-
ioural and Clinical Neuroscience Institute.
Salter, Michael:
Disclosure: None
Scarr, Elizabeth:
Disclosure: This work was support-
ed by the NHMRC and ARC. No conflicts to declare.
Schatzberg, Alan F.:
Disclosure: Disclosure of Fi-
nancial Interest – 1 Year; Alan F. Schatzberg, MD.
2013-Present, Consultant: Bay City Capital,
CeNeRx, Cervel, Eli Lilly, Genentech, Gilead, Lun-
beck/Takeda, McKinsey, Merck, MSI, Naurex, Neu-
ronetics, PharmaNeuroBoost, Xhale, Equity: Am-
nestix, Cervel, Corcept (co-founder), Delpor, Forest,
Merck, Neurocrine, Pfizer, Titan, Xhale, Honoraria:
Merck, Intellectual Property: Named inventor on
pharmacogenetic and antiglucocorticoid use pat-
ents on prediction of antidepressant response.
Schlaepfer, Thomas:
Disclosure: None
Schmidt, Christopher:
Disclosure: In am a full time
employee of Pfizer, Inc.
Scott, Jan:
Disclosure: None
Sheng, Morgan:
Disclosure: Morgan Sheng is a full
time employee of Genentech Inc, a member of the
Roche Group.
Sommer, Wolfgang:
Disclosure: None
Song, Weihong:
Disclosure: None
Sousa, Nuno:
Disclosure: The author has no conflict
of interest.
Stahl, Stephen:
Disclosure: None
Stefansson, Kari:
Disclosure: None
Stein, Dan:
Disclosure: In the past 3 years, Dr. Stein
has received research grants and/or consultancy
honoraria from Biocodex, Lundbeck, Novartis, Ser-
vier, and Sun.
Svensson, Torgny:
Disclosure: Grants/research
support: The Swedish Research Council, The Karo-
linska Institutet, Stockholm (Sweden), The Brain
Foundation (Sweden), AstraZeneca, Organon,
Schering-Plough, Merck Sharp and Dome, Lund-
beck, Otsuka, Astellas; Consultant/advisory board:
AstraZeneca, Janssen, Lundbeck, Otsuka, Merck
Sharp and Dome , Organon, Pfizer, Carnegie Health
Care Funds (Sweden).
Szyf, Moshe:
Disclosure: None
Takahashi, Joseph:
Disclosure: None
Takami, Taro:
Disclosure: None
Turecki, Gustavo:
Disclosure: None
Uher, Rudolf:
Disclosure: None
Ukai, Wataru:
Disclosure: None
Umbricht, Daniel:
Disclosure: I am an employee of
F. Hoffmann-La Roche, Ltd.
Vermetten, Eric:
Disclosure: None
Wang, Gene-Jack:
Disclosure: None
Wang, Yu Tian:
Disclosure: None
Weiner, Ina:
Disclosure: None
Wennogle, Lawrence:
Disclosure: Lawrence Wen-
nogle is a full-time employee of Intra-Cellular Ther-
apies, Inc.
Winstanley, Catharine:
Disclosure: None
Wolosker, Herman:
Disclosure: None
Wong, Dean F.:
Disclosure of the existence of any
significant financial interest or other affiliation with
a funding organization or with a commercial sup-
porter of the session and/or provider of commercial
services. Below is the declaration of relationship to
the funding agencies: Roche: Investigator; Research
funding through JHU contracts; Novartis: Investiga-
tor; Fenoban drug received for research studies;
Merck: Investigator Radiopharmaceutical precursor
received for research studies; NIH: Investigator; Re-
search grants.
Yatham, Lakshmi:
Lakshmi Yatham has received
research grants from Forest, Otsuka, Roche, Shire;
is a consultant to: Genentech, Janssen, Merck, Teva
Novartis, Sunovion, Gruenthal, Boehringer- Ingel-
heim, Lundbeck; and is a speakers bureau member
for Janssen, Merck, Novartis, Sunovion.
Yamawaki, Shigeto:
Disclosure: None
Yan, Riqiang:
Disclosure: I have no conflict of inter-
est to declare. For the funding, my research is fund-
ed by three NIH grants: R01AG025493, NS074256,
and R01AG046 929.
Youdim, Moussa:
Disclosure: None
Young, Trevor:
Disclosure: None
Zarate, Carlos:
Disclosure: Dr Zarate is listed as a
coinventor on a patent application for the use of ket-
amine and its metabolites in major depression. Dr
Zarate has assigned his rights in the patent to the
US government but will share a percentage of any
royalties that may be received by the government.
Zipursky, Robert:
Disclosure: Dr. Zipursky has re-
ceived grant support from Roche and served as a
consultant to Amgen, Sunovion, Otsuka, Lundbeck
and Roche.
Zohar, Joseph:
Disclosure: Joseph Zohar has re-
ceived grant/research support from Lundbeck, Ser-
vier and Pfizer, has served as a consultant or on ad-
visory boards for Servier, Pfizer, Abbott, Lilly,
Actelion, AstraZeneca and Roche, and has served on
speakers’ bureaus for Lundbeck, Roch, and Abbott.
